$59.10
-2.95-4.75%
al cierre: Nov 11, 4:00 PM EST
$59.50
-2.55-4.11%
Premercado: 4:11 AM EST
10x Genomics rose 261.5% from $16.35 to $59.10, ahead of the S&P 500's +12.7%. Its worst day was Oct 6 (−17.5%), and its low came Dec 12 at $15.46.
Story events cover the past 12 months · Times ET
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
10x Genomics closed at its lowest level of the year, 5.4% below where the year started.
−6.5% · S&P 500 −1.1%
EPS of $-0.13 missed the $-0.10 estimate on $166.0M revenue (est. $159.1M); FY revenue guidance of $600.0M–$625.0M against the $624.2M consensus.
+3.5% · S&P 500 +0.1%
10x Genomics shares rose 12.6%, while the S&P 500 fell 0.6%.
+12.6% · S&P 500 −0.6%
EPS of $-0.10 beat the $-0.10 estimate on $150.8M revenue (est. $146.4M); FY revenue guidance of $600.0M–$625.0M against the $612.5M consensus.
−3.7% · S&P 500 +0.8%
10x Genomics shares rose 15.0%, while the S&P 500 rose 0.8%.
+15.0%, the year's best day · S&P 500 +0.8%
EPS of $-0.14 missed the $-0.06 estimate on $151.0M revenue (est. $146.7M); FY revenue guidance of $610.0M–$630.0M against the $613.8M consensus.
+14.1% · S&P 500 +0.6%
10x Genomics closed at its highest level of the year, 497.8% above where the year started.
+4.5% · S&P 500 +0.7%
EPS of $-0.15 missed the $-0.07 estimate on $150.7M revenue (est. $147.7M); FY revenue guidance of $625.0M–$635.0M against the $620.4M consensus.
+2.1% · S&P 500 +0.3%
Where it ended: a close of $59.10 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $-0.07, revenue est. $178.1M).
Nothing in the past 12 months.
All TXG dividend history